CiloTax StentTM - summitMD.com

More documents

Recommendations

Info

Hypothesis The co-drug formulation of cilostazol (6µg/mm2) plus paclitaxel (1µg/mm2) may attenuate the risk of stent thrombosis and potentially reduce the risk of restenosis as <strong>com</strong>pared with paclitaxel alone.
Objectives • to assess safety and efficacy of the Cilotax stent in de novov native coronary lesions. • to <strong>com</strong>pare the performance of a dual DES with that of a standard paclitaxel-eluting stent.
Page 1 and 2: CiloTax Stent TM Dual Drug-eluting
Page 3 and 4: Moving Forward Co-drug Eluting Sten
Page 5 and 6: A Potent Anti-platelet Agent Effect
Page 7 and 8: Anti-restenotic Effect DECLARE - Lo
Page 9 and 10: The Ideal Combination? Cilotax TM S
Page 11 and 12: Cilotax Stent TM Polymer & Drugs Po
Page 13 and 14: Safety and Efficacy of the Cilotax
Page 15 and 16: Animal Preparation • Juvenile swi
Page 17 and 18: Analysis • Angiography and IVUS:
Page 19 and 20: Results 3.0 18mm Cilotax BMS 4 week
Page 21 and 22: IVUS Analysis at Follow-Up (n=7) BM
Page 23 and 24: Results BMS (n=3) Cilotax stent (n=
Page 25 and 26: Results Inflammatory Response BMS (
Page 27: Clinical Study Efficacy and Safety
Page 31 and 32: Study Endpoints • Statistics - a

CiloTax StentTM - summitMD.com

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?